Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

25 mg starter dose of semaglutide-based obesity med Wegovy is now available in the U.S. Last month, the FDA removed Eli Lilly ...

Compounded semaglutide: Medication produced by compounded pharmacies ... the first and only GIP and GLP-1 receptor agonist ...

but it’s “particularly problematic” for GLP-1 drugs—such as semaglutide (Ozempic, Wegovy, and Rybelsus; Novo Nordisk) and ...